Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

NCT06106802 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer Metastatic

Interventions

DRUG: Lazertinib
DRUG: Tepotinib

Sponsor

Samsung Medical Center